T-cell Acute Lymphoblastic Leukemia in Crisis: Hyperleukocytosis, Tumor Lysis Syndrome, and Innovative Approaches

Gordon White; Mariel Duchow; Levy Amar

doi:10.7759/cureus.52017

journal article Jan 10, 2024

T-cell Acute Lymphoblastic Leukemia in Crisis: Hyperleukocytosis, Tumor Lysis Syndrome, and Innovative Approaches

Gordon White Mariel Duchow Levy Amar

Cureus · Springer Science and Business Media LLC

View at Publisher Save 10.7759/cureus.52017

Topics

No keywords indexed for this article. Browse by subject →

References

20

[1]

Marks DI, Rowntree C. Management of adults with T-cell lymphoblastic leukemia. Blood. 2017, 129:1134-42. 10.1182/blood-2016-07-692608 10.1182/blood-2016-07-692608

[2]

Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood. 2012, 119:34-43. 10.1182/blood-2011-04-347872 10.1182/blood-2011-04-347872

[3]

Sentís I, Gonzalez S, Genescà E, et al.. The evolution of relapse of adult T cell acute lymphoblastic leukemia. Genome Biol. 2020, 21:284. 10.1186/s13059-020-02192-z 10.1186/s13059-020-02192-z

[4]

Puckett Y, Chan O. Acute Lymphocytic Leukemia. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023.

[5]

Lee H, Park S, Yoon JH, et al.. The factors influencing clinical outcomes after leukapheresis in acute leukaemia. Sci Rep. 2021, 11:6426. 10.1038/s41598-021-85918-8 10.1038/s41598-021-85918-8

[6]

Abla O, Khanani MF, Hitzler JK, et al.. Complications of hyperleukocytosis and leukapheresis in pediatric acute leukemias. Blood. 2004, 104:1963. 10.1182/blood.V104.11.1963.1963 10.1182/blood.v104.11.1963.1963

[7]

van Buchem MA, te Velde J, Willemze R, Spaander PJ. Leucostasis, an underestimated cause of death in leukaemia. Blut. 1988, 56:39-44. 10.1007/BF00321058 10.1007/bf00321058

[8]

Dutcher JP, Schiffer CA, Wiernik PH. Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. J Clin Oncol. 1987, 5:1364-72. 10.1200/JCO.1987.5.9.1364 10.1200/jco.1987.5.9.1364

[9]

Bug G, Anargyrou K, Tonn T, Bialleck H, Seifried E, Hoelzer D, Ottmann OG. Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis. Transfusion. 2007, 47:1843-50. 10.1111/j.1537-2995.2007.01406.x 10.1111/j.1537-2995.2007.01406.x

[10]

Grund FM, Armitage JO, Burns P. Hydroxyurea in the prevention of the effects of leukostasis in acute leukemia. Arch Intern Med. 1977, 137:1246-7. 10.1001/archinte.1977.03630210112032 10.1001/archinte.1977.03630210112032

[11]

Adeyinka A, Bashir K. Tumor Lysis Syndrome. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2022.

[12]

Padmanabhan A, Connelly-Smith L, Aqui N, et al.. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue. J Clin Apher. 2019, 34:171-354. 10.1002/jca.21705 10.1002/jca.21705

[13]

Bewersdorf JP, Giri S, Tallman MS, Zeidan AM, Stahl M. Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia-a systematic review and meta-analysis. Transfusion. 2020, 60:2360-9. 10.1111/trf.15994 10.1111/trf.15994

[14]

Stahl M, Shallis RM, Wei W, et al.. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia. 2020, 34:3149-60. 10.1038/s41375-020-0783-3 10.1038/s41375-020-0783-3

[15]

Porcu P, Danielson CF, Orazi A, Heerema NA, Gabig TG, McCarthy LJ. Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate. Br J Haematol. 1997, 98:433-6. 10.1046/j.1365-2141.1997.1943011.x 10.1046/j.1365-2141.1997.1943011.x

[16]

Rinaldi I, Sari RM, Tedhy VU, Winston K. Leukapheresis does not improve early survival outcome of acute myeloid leukemia with leukostasis patients - a dual-center retrospective cohort study. J Blood Med. 2021, 12:623-33. 10.2147/JBM.S312140 10.2147/jbm.s312140

[17]

Shallis RM, Stahl M, Bewersdorf JP, Hendrickson JE, Zeidan AM. Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits. Expert Rev Hematol. 2020, 13:489-99. 10.1080/17474086.2020.1751609 10.1080/17474086.2020.1751609

[18]

Kuo KH, Callum JL, Panzarella T, et al.. A retrospective observational study of leucoreductive strategies to manage patients with acute myeloid leukaemia presenting with hyperleucocytosis. Br J Haematol. 2015, 168:384-94. 10.1111/bjh.13146 10.1111/bjh.13146

[19]

Rios-Olais FA, Gil-Lopez F, Mora-Cañas A, Demichelis-Gómez R. Tumor lysis syndrome is associated with worse outcomes in adult patients with acute lymphoblastic leukemia. Acta Haematol. 2023, 10.1159/000534453 10.1159/000534453

[20]

Hölig K, Moog R. Leukocyte depletion by therapeutic leukocytapheresis in patients with leukemia. Transfus Med Hemother. 2012, 39:241-5. 10.1159/000341805 10.1159/000341805

Metrics

1

Citations

20

References

Details

Published: Jan 10, 2024

Authors

Cite This Article

Gordon White, Mariel Duchow, Levy Amar (2024). T-cell Acute Lymphoblastic Leukemia in Crisis: Hyperleukocytosis, Tumor Lysis Syndrome, and Innovative Approaches. Cureus. https://doi.org/10.7759/cureus.52017

T-cell Acute Lymphoblastic Leukemia in Crisis: Hyperleukocytosis, Tumor Lysis Syndrome, and Innovative Approaches

You May Also Like